Idiopathic Pulmonary Fibrosis

Please use this identifier to cite or link to this item: hdl.handle.net/20.500.12104/35779 Title:  PIRFENIDONE LIMITS TH2 FIBROGENIC RESPONSE IN EXPERIMENTAL LIVER FIBROSIS Author:  Novarro-Partida, JMarquez-Aguirre, AMartinez-Rizo, AGonzalez-Cuevas, JGolvez-Gostelum, FJBueno-Topete, MArmendariz-Borunda, J Issue Date:  2008 Publisher:  JOHN WILEY & SONS INC URI:  hdl.handle.net/20.500.12104/35779 ISSN:  0270-9139 Appears in Collections: Producción científica UdeG Files in This Item: There […]

In patients receiving antifibrotic agents, a reduction in the risk of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) may be greater for pirfenidone than for nintedanib, according to the results of a retrospective study published in Respiratory Medicine. AE-IPF is a fatal event that can occur during the clinical course of IPF; however, data from […]

An early phase trial, funded by the National Institute for Health Research (NIHR), has shown that a drug currently used to treat lung fibrosis may also help patients with a common form of heart failure. The trial found that pirfenidone could offer a viable treatment for heart failure with preserved ejection fraction (HFpEF). The study […]

Treatment with two approved antifibrotics did not lessen a risk of death in recently hospitalized idiopathic pulmonary fibrosis (IPF) patients, but those using either therapy who went on to be discharged were more likely to live longer than those who were not, a database study reported. “To our knowledge, this is the first use of real-world […]

© iStock/magicmine A drug currently used to treat lung fibrosis could be repurposed to treat heart failure patients, an early phase trial has suggested. Doctors and scientists from the University of Manchester and Manchester University NHS Foundation Trust, in collaboration with Liverpool Clinical Trials Centre, trialled the drug pirfenidone and found that it could offer […]